Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer

Lorusso D;Hilpert F;González Martin A;Rau J;Ottevanger P;Greimel E;Lück HJ;Selle F;Colombo N;Kroep JR;Mirza MR;Berger R;Pardo B;Grischke EM;Berton-Rigaud D;Martinez-Garcia J;Vergote I;Redondo A;Cardona A;Bastière-Truchot L;du Bois A;Kurzeder C;PENELOPE trial investigators.

2019-01-01